Data/Analytics

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Nurses undeterred by internet bans at work: study

Nurses undeterred by internet bans at work: study

Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.

Drug spend will continue to rise through 2023

Drug spend will continue to rise through 2023

The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.

CDC: Every state has an obesity problem

The latest data shows an overall widening of the US.

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low on doc awareness

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Doctors do not care about your Fitbit

Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.

US diabetes risk jumps to 40%

US diabetes risk jumps to 40%

African-American women had the highest risk of being diagnosed with diabetes—55%. Hispanic men and women were close behind, carrying a 50% risk of being diagnosed with diabetes.

Healthy-habit trackers have short-lived appeal

A study indicates consumers stop using them at the six-month mark.

GAO tallies cost-effective interventions

GAO tallies cost-effective interventions

Half-measures, like diabetes educational materials without a part B, fared poorly.

Open Payments website 'temporarily' taken offline

The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.